Yang Dong Ye, Ouyang Chun Hui, Lu Fang Gen, Liu Xiao Wei, Huang Lai Qiang
The Center for Biotechnology and Biomedicine, Graduate School at Shenzhen, Tsinghua University, Shenzhen, and Department of Gastroenterology, Xiangya Second Hospital, Changsha, Hunan, China.
J Dig Dis. 2007 May;8(2):89-95. doi: 10.1111/j.1443-9573.2007.00291.x.
To testify that the asialoorosomucoid (ASOR) prepared by us has liver-targeting specificity and to investigate its pharmacokinetic characteristics.
The distribution of 125I-ASOR in vivo was determined by single photon emission computed tomography (SPECT) and immunohistochemical technique after 125I-ASOR was injected into Sprague-Dawley (S-D) rats through their caudal veins. In vitro, different doses of pEGFP-N1 plasmid were transfected into both HepG2 cells and HT1080 cells with the use of ASOR-poly-L-lysine. At 24 and 48 h after transfection, the expression of green fluorescent protein (GFP) was determined under fluorescent microscope. Pharmacokinetic parameters were calculated according to two-compartment open system model with first-order kinetics.
SPECT images showed that 125I-ASOR was located only in liver/stomach and root of caudal vein/bladder at 10 min after injection. The 125I-ASOR radioactivities of organs taken out from S-D rats were different at different times, and about 63% of 125I-ASOR was located in the liver at 10 min after injection. At 30 min after injection a peak of radioactivity was seen in stomach. The times of these two radioactivity peaks were different. Immunohistochemical study of liver frozen sections showed that ASOR was combined mainly with hepatocyte membrane, especially in areas with rich blood flow. In vitro study showed that ASOR targeted specifically cells with asialoglycoprotein receptor (ASGr). GFP expression was detected in HepG2 cells but not in HT1080 cells. Furthermore, the more quantity of pEGFP-N1 transfected and the longer expression time, the higher GFP expression level was in HepG2 cells. The 125I-ASOR pharmacokinetics equation for liver was Ct=662216e-3.362t+8896e-2343t. 125I-ASOR was excreted from liver slowly after an initial rapid decrease. The pharmacokinetic equation for stomach was Ct=-114815e-1.7t+1148153e-15t and the half-life of 125I-ASOR in stomach was 4.62 h.
ASOR prepared by us could be an efficient gene transfer vector, ASOR was distributed mainly in the liver and stomach and had high targeting specificity to hepatocytes or hepatic originating cells.
验证我们制备的去唾液酸糖蛋白(ASOR)具有肝靶向特异性,并研究其药代动力学特征。
将125I-ASOR经尾静脉注入Sprague-Dawley(S-D)大鼠后,采用单光子发射计算机断层扫描(SPECT)和免疫组化技术测定125I-ASOR在体内的分布。体外实验中,使用ASOR-聚-L-赖氨酸将不同剂量的pEGFP-N1质粒转染至HepG2细胞和HT1080细胞。转染后24小时和48小时,在荧光显微镜下测定绿色荧光蛋白(GFP)的表达。根据具有一级动力学的二室开放系统模型计算药代动力学参数。
SPECT图像显示,注射后10分钟,125I-ASOR仅位于肝脏/胃以及尾静脉根部/膀胱。从S-D大鼠取出的器官中,125I-ASOR的放射性在不同时间有所不同,注射后10分钟约63%的125I-ASOR位于肝脏。注射后30分钟,胃中出现放射性峰值。这两个放射性峰值的时间不同。肝脏冰冻切片的免疫组化研究表明,ASOR主要与肝细胞膜结合,尤其是在血流丰富的区域。体外研究表明,ASOR特异性靶向具有去唾液酸糖蛋白受体(ASGr)的细胞。在HepG2细胞中检测到GFP表达,而在HT1080细胞中未检测到。此外,转染的pEGFP-N1数量越多、表达时间越长,HepG2细胞中GFP表达水平越高。肝脏的125I-ASOR药代动力学方程为Ct = 662216e-3.362t + 8896e-2343t。125I-ASOR在最初快速下降后从肝脏缓慢排泄。胃的药代动力学方程为Ct = -114815e-1.7t + 1148153e-15t,125I-ASOR在胃中的半衰期为4.62小时。
我们制备的ASOR可能是一种有效的基因传递载体,ASOR主要分布在肝脏和胃,对肝细胞或肝源性细胞具有高靶向特异性。